RVPH Reviva Pharmaceuticals
Price Chart
Executive Summary
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompanying warrants to raise approximately $10 million in gross proceeds. The funds will be used to support the Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia, along with general corporate purposes. The offering includes dual tranches of warrants exercisable immediately at $1.50 per share, with differing expiration terms.
Key Financial Metrics
Actionable Insight
Traders should monitor for immediate downward pressure on RVPH shares due to dilution and the overhang from short-term exercisable warrants. The Series H warrants (12-month expiry) create near-term share supply risk if exercised or if investors sell into the market in anticipation.
Key Facts
- Reviva is raising approximately $10 million through a public offering of 6,666,667 shares and warrants.
- Each share is sold with two warrants: Series G (5-year term) and Series H (12-month term), both exercisable at $1.50.
- The offering is priced at $1.50 per combined unit, below typical market thresholds for sustainable biotech financing.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate needs.
- A.G.P./Alliance Global Partners is the sole placement agent; closing expected March 20, 2026.
Financial Impact
Approximately $10 million in gross proceeds, with significant near-term dilution from short-term warrants.
Risk Factors
- High dilution risk from immediate exercisability of both warrant series, especially the 12-month Series H warrants.
- Low offering price of $1.50 suggests weak investor demand or distressed financing terms.
- Market cap of $14M indicates high risk of volatility and potential for further dilutive offerings.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258719 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
4w ago
|
Press Release
| $0.3900 $0.4194 | ▼ −7.55% | ▼ −8.26% | $0.6839 (−75.36%) |
|
May 13, 2026
4w ago
|
8-K
| $0.3521 $0.4051 | ▼ −15.05% | ▼ −16.21% | $0.6839 (−94.23%) |
|
Apr 15, 2026
8w ago
|
8-K
| $0.8900 $0.9300 | ▲ +4.49% | ▲ +2.86% | $0.6839 (−23.16%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $0.6600 $0.7800 | ▲ +18.18% | ▲ +13.88% | $0.6839 (+3.62%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $0.8300 $0.7800 | ▲ +6.02% | ▲ +3.81% | $0.6839 (+17.60%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $0.8300 $0.7800 | ▼ −6.02% | ▼ −3.81% | $0.6839 (−17.60%) |
|
Mar 5, 2026
14w ago
|
8-K
| $4.20 $2.65 | ▼ −36.90% | ▼ −34.67% | $0.6839 (−83.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access